[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@phsiao4 Paul H, PharmD, RPH

Paul H, PharmD, RPH posts on X about number of, york, ohio, united states the most. They currently have XXX followers and XXX posts still getting attention that total XXX engagements in the last XX hours.

Engagements: XXX #

• X Week XXXXX +682%
• X Month XXXXX +71%
• X Months XXXXX -XX%
• X Year XXXXXX +221%

Mentions: X #

• X Week X +700%
• X Month XX -XX%
• X Months XX +50%
• X Year XXX +60%

Followers: XXX #

• X Week XXX +0.67%
• X Month XXX +1.90%
• X Months XXX +13%
• X Year XXX -XX%

CreatorRank: XXXXXXXXX #

Social Influence #

---

Social category influence countries stocks

Social topic influence number of, york, ohio, united states, bermuda, university of, approved

Top Social Posts #

---

Top posts by engagements in the last XX hours

"-2 Emicizumab (Hemlibra) Faricimab (Vabysmo) Zanidatamab (Ziihera) Zenocutuzumab (Bizengri) Linvoseltamab (Lynozyfic)"
X Link @phsiao4 2025-10-09T23:35Z XXX followers, XX engagements

"Pharmacy Demand Report: Highlights for pharmacist job postings for third quarter of 2025: California had the highest number of job postings (2641) followed by Texas (2080) Florida (1500) New York (1083) and Ohio (1052)"
X Link @phsiao4 2025-10-14T00:16Z XXX followers, XX engagements

"Passionflower is a rapidly growing trailing or climbing perennial or herbaceous perennial. It is a member of the passion vine family (Passifloraceae). It is native to the southeastern and south-central parts of the United States as well as Bermuda"
X Link @phsiao4 2025-10-13T00:40Z XXX followers, XXX engagements

"A gorgeous day (after the first Pacific storm)"
X Link @phsiao4 2025-10-15T01:07Z XXX followers, XX engagements

"University of Minnesota Health Sciences Education Center"
X Link @phsiao4 2025-10-15T17:38Z XXX followers, XXX engagements

"Tarlatamab (Imdellra): Developed by Amgen tarlatamab is a BiTE molecule targeting DLL3 and CD3. It is used for the treatment of small cell lung cancer (SCLC). Approved in 2024"
X Link @phsiao4 2025-10-09T23:38Z XXX followers, XXX engagements